U.S. markets closed

Bonus BioGroup Ltd. (BONS.TA)

Tel Aviv - Tel Aviv Delayed Price. Currency in ILA (0.01 ILS)
Add to watchlist
30.90-0.70 (-2.22%)
At close: 05:24PM IDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close31.60
Bid30.80 x 100
Ask31.10 x 624100
Day's Range30.10 - 32.20
52 Week Range22.10 - 175.00
Avg. Volume6,043,092
Market Cap360.89M
Beta (5Y Monthly)1.86
PE Ratio (TTM)N/A
EPS (TTM)-0.08
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BONS.TA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      ‏Bonus BioGroup's COVID Drug - MesenCure - Can Help a Life-threatening Complication Seen in Cancer Patients

      Haifa-based Biotech company, Bonus BioGroup (TASE: BONS), has recently completed a preclinical trial demonstrating the efficacy of its drug MesenCure (developed for the treatment of severe COVID patients) in reducing life-threatening inflammatory overreaction, seen in patients with cytokine release syndrome (CRS).

    • GlobeNewswire

      POET Technologies to Report Full Year 2021 Financial Results on April 26

      Management to Host Business Update Conference Call on April 27TORONTO, April 21, 2022 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; Nasdaq: POET), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, today announced the Company will distribute its audited consolidated financial results for the fourth quarter and full year ended December 31, 2021 after the cl

    • Newsfile

      Bonus BioGroup Submits Outstanding Phase-II Trial Results for MesenCure, a Treatment for Severe COVID-19, to the Israeli Ministry of Health

      Tel Aviv, Israel--(Newsfile Corp. - January 18, 2022) - Bonus BioGroup (TASE: BONS) or "the Company", a clinical-stage Israeli biotechnology company engaged in the research and development of biomedical tissue-engineered and cell therapy products, submitted results for its multicenter, Phase-II clinical trial to the Israeli Ministry of Health on January 9th. Following on the heels of the Company's initial release of encouraging preliminary results in November 2021, the trial data submitted last